Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.57 |
| ▸ | KIT | P10721 | 4/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.49 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038584 | 0.91 | HPGD (0.57) | FLT3KITIRAK4LRRK2ALDH1A1 | |
| SCHEMBL12780207 | 0.90 | FLT3 (0.52) | FLT3KITIRAK4LRRK2ALDH1A1 | |
| SCHEMBL4037633 | 0.88 | FLT3 (0.60) | FLT3KITIRAK4LRRK2MAP3K9 | |
| SCHEMBL14369764 | 0.84 | FLT3 (0.58) | FLT3KITIRAK4LRRK2MAP3K9 | |
| SCHEMBL4047470 | 0.84 | FLT3 (0.57) | FLT3KITIRAK4LRRK2MAP3K9 | |
| SCHEMBL4207870 | 0.81 | JAK2 (0.59) | FLT3KITIRAK4JAK2ALDH1A1 | |
| SCHEMBL4038190 | 0.81 | FLT3 (0.72) | FLT3KITIRAK4LRRK2JAK2 | |
| SCHEMBL12780341 | 0.79 | KIT (0.71) | FLT3KITIRAK4LRRK2MAP3K9 | |
| SCHEMBL4042660 | 0.77 | FLT3 (0.59) | FLT3KITIRAK4LRRK2MKNK2 | |
| SCHEMBL12780334 | 0.75 | KIT (0.68) | FLT3KITIRAK4LRRK2MAP3K9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | FLT3 191/4885KIT 518/4885IRAK4 527/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885KIT 1144/4885IRAK4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.